Oncology

Recursion, Roche, Genentech collaborate in neuroscience, oncology

Recursion, a clinical-stage biotechnology company, has announced a collaboration with Roche and Genentech, a member of the Roche Group.

US FDA grants priority review to AstraZeneca’s sNDA for breast cancer therapy

The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) to treat BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer patients.

Stingthera, Merck to collaborate to analyse SNX281 with Keytruda

 Stingthera has signed a clinical trial collaboration agreement with Merck to analyse the combination of investigational SNX281 and Keytruda (pembrolizumab) in some patients with advanced solid tumours and lymphoma.

AbbVie to acquire TeneoOne and multiple myeloma drug from Teneobio

AbbVie is set to acquire Teneobio affiliate TeneoOne and its lead drug candidate TNB-383B, which is being developed to treat relapsed or refractory multiple myeloma (R/R MM).

GSK, iTeos Therapeutics to co-develop and co-commercialise cancer drug

GlaxoSmithKline (GSK) and iTeos Therapeutics have signed an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody presently under phase I development as a potential treatment for cancer patients.

BMS signs cancer therapy deal worth $1.5bn with Agenus

Bristol-Myers Squibb (BMS) has agreed to obtain a worldwide exclusive licence to a cancer antibody programme, AGEN1777, and a second undisclosed target developed by immuno-oncology firm Agenus.

Dr. Reddy’s signs license deal for anti-BCMA CAR-T PRG1801 in India

Dr. Reddy's Laboratories has signed an agreement with Shenzhen Pregene Biopharma to acquire an exclusive license in India for PRG1801, Pregene's single domain antibody-based anti-BCMA chimeric antigen receptor T (CAR-T) cell therapy injection.

Second indication of Sarclisa for relapsed multiple myeloma approved by EC

The second indication of Sarclisa (isatuximab) for the treatment of adult patients with relapsed multiple myeloma, was approved by the European Commission (EC).

Trodelvy granted accelerated approval by USFDA for metastatic urothelial cancer

Gilead Sciences has announced the accelerated approval of Trodelvy (or sacituzumab govitecan-hziy) by the US Food and Drug Administration (FDA) in the treatment of locally advanced or metastatic urothelial cancer (UC) in adult patients.